This unique HER2 scoring model does not rely on challenging manual intervention and is proven to be a simple and robust tool for pathologists to improve the accuracy of HER2 interpretation and provides a clinical aid to target therapy in BC patients. The gene discussed is ERBB2; the disease is breast cancer.